Pharmacogenetics and precision medicine approaches for the improvement of COVID-19 therapies

M Biswas, N Sawajan, T Rungrotmongkol… - Frontiers in …, 2022 - frontiersin.org
Many drugs are being administered to tackle coronavirus disease 2019 (COVID-19)
pandemic situations without establishing clinical effectiveness or tailoring safety. A …

Will the use of pharmacogenetics improve treatment efficiency in COVID-19?

B Franczyk, J Rysz, J Miłoński, T Konecki… - Pharmaceuticals, 2022 - mdpi.com
The COVID-19 pandemic is associated with a global health crisis and the greatest challenge
for scientists and doctors. The virus causes severe acute respiratory syndrome with an …

Important pharmacogenetic information for drugs prescribed during the SARS‐CoV‐2 infection (COVID‐19)

P Zubiaur, D Koller, M Saiz‐Rodríguez… - Clinical and …, 2020 - Wiley Online Library
In December 2019, the severe acute respiratory syndrome virus‐2 pandemic began,
causing the coronavirus disease 2019. A vast variety of drugs is being used off‐label as …

Pharmacogenomics and pharmacogenetics: in silico prediction of drug effects in treatments for novel coronavirus SARS-CoV2 disease

C Cafiero, A Re, A Micera, R Palmirotta… - Pharmacogenomics …, 2020 - Taylor & Francis
The latest developments in precision medicine allow the modulation of therapeutic
approaches in different pathologies on the basis of the specific molecular characterization of …

Pharmacogenetics approach for the improvement of COVID-19 treatment

I Fricke-Galindo, R Falfán-Valencia - Viruses, 2021 - mdpi.com
The treatment of coronavirus disease 2019 (COVID-19) has been a challenge. The efficacy
of several drugs has been evaluated and variability in drug response has been observed …

Pharmacogenomics of COVID-19 therapies

T Takahashi, JA Luzum, MR Nicol… - NPJ genomic …, 2020 - nature.com
A new global pandemic of coronavirus disease 2019 (COVID-19) has resulted in high
mortality and morbidity. Currently numerous drugs are under expedited investigations …

Pharmacogenomics and COVID-19: clinical implications of human genome interactions with repurposed drugs

OA Badary - The pharmacogenomics journal, 2021 - nature.com
The outbreak of Coronavirus disease 2019 (COVID-19) has evolved into an emergent global
pandemic. Many drugs without established efficacy are being used to treat COVID-19 …

Genomics insights of SARS-CoV-2 (COVID-19) into target-based drug discovery

P Chellapandi, S Saranya - Medicinal Chemistry Research, 2020 - Springer
Abstract Coronavirus disease (COVID-19) pandemic is caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2). COVID-19 is a global health emergency and no …

Complex analysis of the personalized pharmacotherapy in the management of COVID-19 patients and suggestions for applications of predictive, preventive, and …

LY Wang, JJ Cui, QY OuYang, Y Zhan, YM Wang… - EPMA Journal, 2021 - Springer
Abstract Aims Coronavirus disease 2019 (COVID-19) is rapidly spreading worldwide. Drug
therapy is one of the major treatments, but contradictory results of clinical trials have been …

Computational drug discovery and repurposing for the treatment of COVID-19: A systematic review

K Mohamed, N Yazdanpanah, A Saghazadeh… - Bioorganic …, 2021 - Elsevier
Background Since the beginning of the novel coronavirus (SARS-CoV-2) disease outbreak,
there has been an increasing interest in finding a potential therapeutic agent for the disease …